#USA #San Jose #medical technology #Vantis Vascular #CrossFAST

Vantis Vascular Closes $10M Series B-1 Preferred Financing

Vantis Vascular, Inc., a cutting-edge medical technology firm, has recently announced the successful closure of a $10 million Series B-1 preferred financing round. This follows a previous fundraising achievement of $30 million from both affluent individuals and steady support from National Institutes of Health grants. The investments mark a significant step in Vantis Vascular's mission to transform vascular interventions through innovative technology originally conceived by a team of physicians.

A Vision for Revolutionizing Vascular Interventions

Jason Turner, the company’s CEO, expressed pride in the ongoing support from investors who share in the vision of revolutionizing complex interventional procedures. This funding acts as a pivotal milestone for Vantis, promising to boost product development efforts, expand their workforce, and initiate the U.S. commercialization of their flagship product, the CrossFAST™ Integrated Microcatheter Advanced Delivery System, specifically tailored for high-risk percutaneous coronary interventions (PCI).

The CrossFAST System: A Game Changer

The CrossFAST System stands out as the first dual monorail microcatheter advanced delivery system uniquely designed for intricate coronary and peripheral interventions. Traditional guide extension catheters often fall short in reaching targeted areas during high-risk PCIs and carry risks of inflicting vessel trauma as well as damaging previously placed stents. In stark contrast, the CrossFAST Advanced Delivery System features an integrated microcatheter, enabling a seamless transition that minimizes the likelihood of adverse events.

Equipped with DuoPRO™ Interlocking Technology, the CrossFAST System facilitates a robust connection between the microcatheter and the outer delivery catheter. This innovation allows for a unified advancement of both components, greatly enhancing pushability and navigation – aspects that often plague conventional guide extension catheters, particularly in complex and high-stakes procedures.

Gary McCord, the Chief Commercial Officer, noted that the company is eager to kick off the limited market release of the CrossFAST System in the United States following this financing milestone. He emphasized the confidence the team has in the CrossFAST System's capability to navigate through challenging anatomies, such as calcified and tortuous pathways. This technology aims to empower physicians, subsequently leading to more effective delivery methods for life-saving therapies.

Market Availability and Future Plans

Currently, the CrossFAST Integrated Microcatheter Advanced Delivery System is available in the United States under a limited market release. Full-scale market release is projected for 2025, opening up potential for broader applications of this pioneering technology.

Vantis Vascular remains dedicated to its mission of advancing the field of interventional cardiology using performance-driven technologies. Founded by medical professionals focused on improving treatment methodologies, Vantis continually seeks to enhance patient outcomes through innovation and research-driven solutions. As they step forward into commercialization, the medical industry is watching closely, anticipating how this technology could streamline procedures that significantly impact patient lives.

In conclusion, with the successful closure of the recent funding round, Vantis Vascular is poised to advance the frontier of vascular interventions significantly. Their commitment to innovation not only supports their growth ambitions but also pledges to enhance medical practices and patient safety in critical care settings.